HRA Pharma Reveals Big Growth Ambitions In Quest To Become Top-10 OTC Player

12 Dec 2018

A combination of prescription-to-OTC switches, acquisitions and maximising the potential of its existing portfolio will take France’s HRA Pharma to the next level, reveals chief commercial officer Martyn Hilton.

HRA Pharma's Martyn Hilton • Source: Mark Earthy

French firm HRA Pharma SA is focused on more than doubling its sales over the next four years by maximizing the potential of its leading OTC brands, says its chief global commercial officer, Martyn Hilton. Its long-term ambition, with the help of acquisitions, is to become a top 10 consumer healthcare player globally.

Speaking at the 13th annual Ceuta International Alliance conference in London, Hilton said HRA wanted to grow the business from expected revenues of around €211m ($239

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Danes Get OTC Access To ED Treatment

08 May 2025

• By Tom Gallen

Navamedic has launched Eroxon in Danish pharmacies giving men in the country OTC access to an ED treatment for the first time.

Haleon Targets Low Income Households In Push To Reach 1bn More Consumers

07 May 2025

• By Tom Gallen

Haleon wants to reach one billion more consumers by 2030 and plans to do this by tailoring products to those outside the highest income bracket. The UK-based firm's five-year growth plan will also see it generate £0.8bn in productivity savings.

People On The Move: Appointments At Haleon, Wellnex, Orkla

06 May 2025

• By Tom Gallen

A round-up of the latest consumer health leadership changes: Haleon names Middle East & Africa unit manager; Wellnex Life appoints interim chair; Orkla Health appoints CEO.